Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Poderá a Fotobiomodulação Aguda Melhorar o Equilíbrio e a Cognição em Indivíduos com Ataxia: um Ensaio de Viabilidade Piloto Controlado Randomizado com Placebo.

20 de setembro de 2026 atualizado por: Jonathan Sinclair, University of Central Lancashire

Pode a Fotobiomodulação Aguda Melhorar o Equilíbrio e a Cognição em Indivíduos com Ataxia: um Ensaio de Viabilidade Controlado Randomizado com Placebo.

Cerebellar ataxias cause progressive impairments in balance, gait coordination, motor timing, and cognitive functions such as attention and executive control (Buckner, 2013; Salmi et al., 2010; Timmann & Daum, 2007). These symptoms substantially reduce independence and quality of life, and current treatments remain limited. There is an urgent need for safe, low-burden interventions that can support everyday functioning and potentially enhance compensatory neural processes.

Transcranial photobiomodulation (tPBM) uses red and near-infrared light (600-1100 nm) to modulate mitochondrial cytochrome-c oxidase, increasing ATP production, reducing oxidative stress, and improving cerebral blood flow (Hamblin, 2016; Salehpour et al., 2019). Several studies show that tPBM can acutely improve cognitive performance and motor control in both healthy adults and clinical groups (Barrett & Gonzalez-Lima, 2013; Chan et al., 2019; Henderson & Morries, 2017). A growing neurobiological literature suggests that light can penetrate posterior cortical areas sufficiently to modulate networks involving cerebellar-cortical loops (Jagdeo et al., 2012).

Importantly for ataxia, preliminary work shows that tPBM may acutely improve balance stability and gait metrics in older adults and patients with neurological conditions (Moro et al., 2022; Shin et al., 2021). In our own laboratory, we have observed immediate improvements in sway range and cognitive control in older adults after a 24-minute tPBM session applied over midline and posterior scalp regions. These medium to large size effects are consistent with enhanced sensorimotor integration and improved control of attention in distracting environments.

Given that individuals with cerebellar ataxia experience both motor incoordination and difficulties in maintaining cognitive stability under distracting conditions, tPBM is a promising non-pharmacological intervention worth preliminary investigation.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Tipo de estudo

Intervencional

Inscrição (Estimado)

20

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 70 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age 18-70 years (inclusive)
  • Diagnosis of ataxia
  • Able to walk independently for at least 5 minutes, with or without an assistive device
  • Able to stand safely for balance testing, with or without an assistive device
  • Hemodynamically stable (stable blood pressure and heart rate at rest)
  • On a stable medication regimen for ≥4 weeks prior to enrolment
  • Sufficient vision and hearing (with usual aids if required) to complete balance and cognitive assessments
  • Able to complete study questionnaires and cognitive tasks (with assistance for reading/writing if required)
  • Able and willing to provide written informed consent

Exclusion Criteria:

  • Current or past history of head injury
  • Use of medications acting on the central nervous system
  • Active skin conditions on the forehead or scalp
  • Any other major neurological disorder that could independently affect balance or cognition
  • Ongoing brain stimulation therapy
  • History of migraines
  • Sensitive skin, allergies

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador de Placebo: Sham Comparator: Sham photobiomodulation

Sham photobiomodulation. The sham device will follow the same protocol but without active light emission.

The sham device will follow the same protocol but without active light emission.

Experimental: Photobiomodulation

Acute photobiomodulation Twenty-four-minute photobiomodulation stimulation (twelve minutes at 670 nm followed by twelve minutes at 810 nm).

Photobiomodulation

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
n-1-back (deviation)
Prazo: Baseline

The n-1-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-1 trials earlier.

Baseline
n-1-back (deviation)
Prazo: 1 hour

The n-1-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-1 trials earlier.

1 hour

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
n-2-back (deviation)
Prazo: Baseline

The n-2-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-2 trials earlier.

Baseline
n-2-back (deviation)
Prazo: 1 hour

The n-2-back (deviation) task is a working memory test where participants respond when the current stimulus differs from the one presented n-2 trials earlier.

1 hour
n-1-back (post-deviation)
Prazo: Baseline

The n-1-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-1 trials earlier.

Baseline
n-1-back (post-deviation)
Prazo: 1 hour

The n-1-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-1 trials earlier.

1 hour
n-2-back (post-deviation)
Prazo: Baseline

The n-2-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-2 trials earlier.

Baseline
n-2-back (post-deviation)
Prazo: 1 hour

The n-2-back (post-deviation) task assesses working memory performance on the trial immediately following a deviation from the stimulus presented n-2 trials earlier.

1 hour
n-1-back (post-target)
Prazo: Baseline

The n-1-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-1 trials earlier.

Baseline
n-1-back (post-target)
Prazo: 1 hour

The n-1-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-1 trials earlier.

1 hour
n-2-back (post-target)
Prazo: Baseline

The n-2-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-2 trials earlier.

Baseline
n-2-back (post-target)
Prazo: 1 hour

The n-2-back (post-target) task assesses working memory performance on the trial immediately following a target that matched the stimulus presented n-2 trials earlier.

1 hour
n-1-back (load)
Prazo: Baseline

The n-1-back (load) condition measures working memory performance under the cognitive demand of tracking stimuli 1 trial back.

Baseline
n-1-back (load)
Prazo: 1 hour

The n-1-back (load) condition measures working memory performance under the cognitive demand of tracking stimuli 1 trial back.

1 hour
n-2-back (post-load)
Prazo: Baseline

The n-2-back (post-load) condition assesses working memory performance on the trial immediately following a high cognitive load in the n-2-back task.

Baseline
n-2-back (post-load)
Prazo: 1 hour

The n-2-back (post-load) condition assesses working memory performance on the trial immediately following a high cognitive load in the n-2-back task.

1 hour
Coop-Wonka chart
Prazo: Baseline

The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring system for each thus the chart has a maximum score of 30 which indicates the lowest possible psychological Wellbeing.

Baseline
Coop-Wonka chart
Prazo: 1 hour

The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring system for each thus the chart has a maximum score of 30 which indicates the lowest possible psychological Wellbeing.

1 hour
Beck Depression Inventory
Prazo: Baseline

Psychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible.

Baseline
Beck Depression Inventory
Prazo: 1 hour

Psychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible.

1 hour
Pittsburgh Sleep Quality Index
Prazo: Baseline

The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.

Baseline
Pittsburgh Sleep Quality Index
Prazo: 1 hour

The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components. Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.

1 hour
State Trait Anxiety Inventory
Prazo: Baseline

The state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety.

Baseline
State Trait Anxiety Inventory
Prazo: 1 hour

The state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety.

1 hour
Insomnia Severity Index
Prazo: Baseline

The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia. The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28.

Baseline
Insomnia Severity Index
Prazo: 1 hour

The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia. The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28.

1 hour
Epworth Sleepiness Scale
Prazo: Baseline

The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24.

Baseline
Epworth Sleepiness Scale
Prazo: 1 hour

The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24.

1 hour
Everyday Memory Errors Questionnaire
Prazo: Baseline

The Everyday Memory Errors Questionnaire is a brief self-report instrument designed to assess the frequency of memory lapses in daily life. It consists of multiple items that yield a total score reflecting the extent of everyday memory difficulties.

Baseline
Everyday Memory Errors Questionnaire
Prazo: 1 hour

The Everyday Memory Errors Questionnaire is a brief self-report instrument designed to assess the frequency of memory lapses in daily life. It consists of multiple items that yield a total score reflecting the extent of everyday memory difficulties.

1 hour
Falls Efficacy
Prazo: Baseline

The Falls Efficacy Scale is a brief self-report instrument designed to assess confidence in performing daily activities without falling. It consists of multiple items that yield a total score reflecting fear of falling and perceived fall-related self-efficacy.

Baseline
Falls Efficacy
Prazo: 1 hour

The Falls Efficacy Scale is a brief self-report instrument designed to assess confidence in performing daily activities without falling. It consists of multiple items that yield a total score reflecting fear of falling and perceived fall-related self-efficacy.

1 hour
Anterior-posterior balance
Prazo: Baseline

The maximum anterior-posterior displacement of the centre of pressure during a two-minute balance task.

Baseline
Anterior-posterior balance
Prazo: 1 hour

The maximum anterior-posterior displacement of the centre of pressure during a two-minute balance task.

1 hour
Medio-lateral balance
Prazo: Baseline

The maximum medio-lateral displacement of the centre of pressure during a two-minute balance task.

Baseline
Medio-lateral balance
Prazo: 1 hour

The maximum medio-lateral displacement of the centre of pressure during a two-minute balance task.

1 hour

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de janeiro de 2027

Conclusão Primária (Estimado)

1 de junho de 2027

Conclusão do estudo (Estimado)

10 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

8 de dezembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

8 de dezembro de 2025

Primeira postagem (Real)

22 de dezembro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

20 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever